IPA (ImmunoPrecise Antibodies)

About:

IPA is a full-service, bioplatform-based and AI-driven company, specialized in next-gen antibody discovery for therapeutics.

Website: https://ipatherapeutics.com/

Twitter/X: immunoprecise

Top Investors: Yorkville Advisors, Brisio Innovations, North Dakota Department of Agriculture

Description:

IPA is a biotherapeutic research and technology company that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Recently, IPA was ranked by one of the pharmaceutical industry’s most trusted and independent market research sources as having the highest competitive score for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, providing highly specialized full-continuum therapeutic antibody discovery and development —with advanced omics and complex artificial intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before.  Our mission is to provide a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal is to support the advancement of novel biologics against even the most challenging targets, ultimately contributing to the treatment of diseases and the betterment of humankind. Footnote: 1. ROOTS 2022: Antibody Discovery Services and Platforms Market